NEW YORK--(BUSINESS WIRE)--OrbiMed is pleased to announce two new team additions who are among the global biotechnology industry’s most talented and capable professionals.
Tal Zaks, M.D., Ph.D., joined OrbiMed as a Venture Partner. Dr. Zaks was recently the Chief Medical Officer at Moderna, where he led the development of the company’s Covid-19 vaccine and other key programs. Previously, Dr. Zaks held senior leadership positions in drug development at major pharmaceutical companies, including Sanofi and GlaxoSmithKline. Dr. Zaks received his M.D. and Ph.D. from Ben-Gurion University and conducted post-doctoral research at the U.S. National Institutes of Health.
Sheila Gujrathi, M.D., joined OrbiMed as a Venture Advisor. Dr. Gujrathi was the Chief Executive Officer and Co-Founder of Gossamer Bio. Prior to Gossamer, Dr. Gujrathi served as the Chief Medical Officer of Receptos, which Celgene acquired. Previously, Dr. Gujrathi held development leadership positions at Bristol-Myers Squibb and Genentech and was a McKinsey consultant. Dr. Gujrathi received her M.D. and B.S. in biomedical engineering from Northwestern University’s Honors Program in Medical Education and clinically trained at Brigham and Women’s Hospital, UCSF, and Stanford.
OrbiMed ranks among the largest and most prolific life sciences investors in recent decades, backing over 80 start-ups since inception. Over 60 new healthcare therapies have been successfully developed and brought to patients by OrbiMed’s private portfolio companies.
“We are excited to welcome Tal and Sheila to the OrbiMed team,” stated Carl Gordon, a Managing Partner and Head of Private Equity at OrbiMed. “We are confident they will make transformative contributions to the growth and success of OrbiMed’s venture capital investments.”
About OrbiMed
OrbiMed is a leading healthcare investment firm, with $18 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.